Latest ArticlesIn 2024, FDA approved 50 new drugs, including 31 chemical small molecules and 19 biological products. This review describes the descriptions, indications, mechanism of action, dosage forms and strengths, adverse reactions, and synthesis routes of all the small molecules, and the basic information about biological products.
Peptide-drug conjugates(PDCs) are emerging targeted drugs, composed of payloads, linkers, and homing peptides. By homing peptides, cytotoxic molecules or radionuclides can be enriched in cells of diseased tissues,thereby reducing the toxicity to normal cells. With the advantages of high selectivity, high tissue penetration, and low immunogenicity, PDCs have become a hot spot in the development of a new generation of targeted antineoplastic drugs following antibody-drug conjugates(ADCs). Nevertheless, PDCs still face some challenges, such as poor in vivo stability,and low receptor affinity. This paper reviews the composition, clinical application progress, key technologies, and challenges of PDCs, aiming to provide some references for the development and application of PDCs.
Bruton’s tyrosine kinase(BTK) plays a crucial role in the development, proliferation, differentiation,activation and cytokine secretion of B cells. BTK inhibitors(BTKIs) can effectively block downstream cell signaling and receptor activation by blocking BTK or inhibiting its activity, and produce negative feedback on upstream signaling molecules related to the occurrence and development of various diseases, so as to playing a therapeutic role. In the research and development of BTKIs, the target occupancy, serving as an evaluation indicator of the binding affinity of drugs to BTK,has become an important pharmacodynamic parameter in preclinical and clinical studies. Besides, it not only reflects the relationship between dose and target occupancy, but also has important significance for establishing the relationship between efficacy and target occupancy. This paper reviews the evaluation methods of BTKI target occupancy, and discusses the advantages and disadvantages of these methods, aiming to provide some references for selecting suitable target occupancy evaluation methods in the research and development process of BTKI.
In this paper, the synthetic route of phenylephrine hydrochloride(1) was improved. 3-Hydroxyaceto-phenone(2) was used as the starting material to synthesize 2-chloro-1-(3-hydroxyphenyl)ethan-1-one(3) by reacting with sulfonyl chloride. Compound 3 was transformed into 1-(3-hydroxyphenyl)-2-[benzyl(methyl)amino]ethan-1-one(4)through nucleophilic substitution with N-methylbenzylamine. (R)-3-[2-[Benzyl(methyl)amino]-1-hydroxyethyl]phenol(5)was stereoselectively synthesized from 4 via reduction by the engineered bacteria containing carbonyl reductase A12.Compound 1 was obtained from 5 with the purity of 99.9% and ee value of up to 99.9% by palladium carbon debenzylation and salification, and the total yield reached to 62.8%(based on 2). The improved synthetic route had the characteristics of simple operation and high yield, which was suitable for industrial production.
Based on the new synthetic route of deoxycholic acid(1) reported by this group, nine related substances of 1 were prepared in this paper, including eight process impurities, i.e. related substances A(7), C(8), D(9), E(10),F(11), B(12), H(13), I(14) , and one degradation impurity J(3). Among them, compounds 8, 9 and 13 were reported at the first time. The structures of these compounds were confirmed by 1H NMR and MS.
To improve the yield of cyclosporin A(1) produced by Fusarium solani, this study optimized the types and amounts of the key components in the fermentation medium for 1 production, including the carbon source, organic nitrogen source, and amino acid by single factor experiment and Box-Behnken design coupled with response surface methodology. The optimized formulation was as follows: glucose 31.3 g/L, maltodextrin 62.7 g/L, casein 17.3 g/L, yeast extract LM801 8.7 g/L, L-valine 7.15 g/L. Under these conditions, the yield of 1 by shake flask culture was increased to 4 283 mg/L. Then, the effects of different supplementation processes on the yield of 1 were investigated. Finally, the yield of 1 reached to 5 247 mg/L in a 25 L fermentor using fluid-feeding, which was 72.49% higher than that of the original formulation.This study provided some references for the industrial production of 1.
Nimodipine(1) solid dispersion(SD) was prepared by hot melt extrusion, and the tablets based on 1-SD were prepared by direct compression method. Taking the in vitro dissolution as an indicator, the impacts of filler type,type and amount of disintegrants on drug dissolution of 1-SD tablets were investigated. The results showed that the tablets prepared with potassium dihydrogen phosphate as the filler and the effervescent agent[m(sodium bicarbonate)∶m(citric acid)=5∶4] as the disintegrant exhibited a favorable dissolution behavior. The 1-SD tablets prepared with the optimized formulation(containing 240 mg of 1-SD, 124 mg of potassium dihydrogen phosphate, 32 mg of above disintegrant, and 4 mg of magnesium stearate) disintegrated in 5 min, and their dissolution rate at 10 min could be over 95%. The 1-SD tablets prepared in this study effectively overcame the gel barrier produced by the hydrophilic carrier and had a good dissolution performance, which provided a reference for the development of SD tablets.
In this study, the formulation of ferulic acid(1) cream was optimized by single-factor experiments combined with Box-Behnken design-response surface methodology. Subsequently, the in vitro permeation behavior of the 1 creams was investigated with excised rat skin, and its pharmacokinetics in rats was also explored. The obtained optimal formulation was as follows: the mass fractions of 1, azone, mint oil, 1,2-propanediol and PEG400 were 5.00%,10.68%, 10.03%, 9.32% and 10.00%, respectively. The results of in vitro permeation test showed that the cumulative permeation amount of the 1 cream prepared by the optimal formulation within ten hours was (470.70±24.54)μg/cm², and the permeation rate was (57.70±3.09)μg·cm–2·h–1. The results of in vivo studies indicated that after transdermal administration of the 1 cream to rats, AUC could reach to (953.90±175.30)mg·min·L–1 at 10 h, which was equivalent to that of intragastric administration at a dose of 10 mg/kg. Moreover, the plasma concentration of 1 in rats in the transdermal administration group did not show a decreasing trend within 10 h. This study demonstrated that the preparation process of 1 cream was simple and easy to be industrialized, and the prepared cream had good transdermal absorption and could release the drug stably for a long time, providing a reference for the further development and application of 1.